Diamyd Medical to present at upcoming scientific conferences

The meta-analysis that describes the genetically defined responder groups to Diamyd® treatment will be presented at the Precision Diabetes Medicine 2021 meeting (PMD) in April and at the 14th International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) in June.

CEO Ulf Hannelius, Diamyd Medical, will present a poster entitled “Accelerating precision therapies for T1D by targeting genetic responder groups - the influence of HLA haplotype on GAD-specific immunotherapy” at PMD 2021. The conference is organized by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) and  will take place as a virtual meeting on 8-10 April 2021. The conference website can be accessed through www.pdm2021.org

At ATTD, Ulf Hannelius will give an oral presentation titled “Novel treatment of type 1 diabetes - the influence of HLA, number of doses and administration route on the effect of GAD-specific immunotherapy”. The conference will take place as a virtual meeting on 2-5 June 2021. The conference website can be accessed through  https://attd.kenes.com/


Diamyd Medical will also participate at the upcoming 3rd Annual Articial Intelligence and Machine Learning for Advanced Drug Discovery and Development Forum,  where Ulf Hannelius will be presenting, and participate in a panel discussion. The presentation is entitled “Precision Medicine and Antigen-Specific Immunotherapy in Type 1 Diabetes – The Potential for Machine Learning”. The conference will take place as a virtual meeting on 13-14 April. The conference website can be accessed through https://www.bisgrp.com/event/3rd-annual-artificial-intelligence-and-machine-learning-for-advanced-drug-discovery-and-development-forum

About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication 29 March 2021, 12.00 CET.


  PDF version